A detailed history of Avanza Fonder Ab transactions in Exact Sciences Corp stock. As of the latest transaction made, Avanza Fonder Ab holds 13,535 shares of EXAS stock, worth $598,923. This represents 0.02% of its overall portfolio holdings.

Number of Shares
13,535
Previous 19,512 30.63%
Holding current value
$598,923
Previous $1.1 Billion 44.99%
% of portfolio
0.02%
Previous 0.03%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 15, 2025

SELL
$43.04 - $58.51 $257,250 - $349,714
-5,977 Reduced 30.63%
13,535 $603 Million
Q4 2024

Jan 15, 2025

BUY
$49.33 - $71.97 $962,526 - $1.4 Million
19,512 New
19,512 $1.1 Billion

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $7.83B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Avanza Fonder Ab Portfolio

Follow Avanza Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avanza Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Avanza Fonder Ab with notifications on news.